SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH M impact

CALC: Continues Auxora Dosing

CalciMedica receives no FDA comments on its Phase 2 KOURAGE trial submission, allowing continued patient dosing with Auxora

CALC

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.